Last updated: February 15, 2026
Overview of the Drug
NDC 00078-0867 corresponds to Remicade (infliximab), a monoclonal antibody biologic used to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis. Remicade has received multiple FDA approvals since its original approval in 1998, with additional indications added over time. It competes in a high-value biologic market, facing patent expiration and biosimilar entries.
Market Size and Growth Dynamics
Current Market Size (2022-2023)
- Estimated global sales of infliximab products, including Remicade and biosimilars, totaled approximately $8.5 billion in 2022 (source: IQVIA).
- The U.S. market accounts for roughly 50% of this value, approximating $4.2 billion.
- Leading indication segments include rheumatoid arthritis and inflammatory bowel disease (IBD).
Key Market Drivers
- Increasing prevalence of autoimmune conditions.
- Expansion of indications for infliximab.
- Market penetration by biosimilars, leading to price competition.
- Pricing pressures from healthcare payers and policymakers aiming to reduce biologic costs.
Competition Landscape
- Original biologic: Remicade (Johnson & Johnson/Merck partnership).
- Biosimilars introduced since 2016: Inflectra, Renflexis, Avsola, and Zessly.
- Biosimilar market share in the U.S.: Reached approximately 35-40% by late 2022, with growth expected.
- Patent expirations for Remicade occurred in the U.S. and Europe around 2018-2019, allowing biosimilar entry.
Price Projections
Historical Pricing Trends
- Remicade's list price in the U.S. around 2018: approximately $2,500 per 100 mg vial.
- Post-biosimilar entry, list prices declined by 15-25% within two years.
- Average wholesale prices (AWP) for biosimilars: range from $1,800 to $2,000 per 100 mg vial.
Future Price Trajectory (2023-2028)
| Year |
Average Price per 100 mg Vial |
Comments |
| 2023 |
$1,950 |
Stabilization after initial biosimilar price dips. |
| 2024 |
$1,900 |
Slight decrease; biosimilar market penetration continues. |
| 2025 |
$1,850 |
Increased biosimilar competition drives prices lower. |
| 2026-28 |
$1,750 - $1,800 |
Further market consolidation; biosimilar pricing stabilizes. |
Sources: IQVIA, Wolfe Research, Scrip Intelligence.
Factors Affecting Price Projections
- Biosimilar uptake rates, potentially reaching 60% of market share by 2028.
- Reimbursement policies and biosimilar interchangeability regulations.
- Patent litigation outcomes and exclusivity extensions.
- New indications or formulations influencing demand.
Revenue Impact and Market Share Forecast
- Assuming a 50% market share for biosimilars by 2028.
- Considering current annual sales (~$4.2 billion in the U.S.), the total infliximab market could decline marginally or stabilize due to volume increases in existing indications.
- Biosimilar sales projected to reach $3 billion in the U.S. alone by 2028, with price erosion mitigating revenue growth for the originator.
Regulatory and Policy Considerations
- U.S. FDA approved multiple biosimilars for infliximab.
- Increasing policy support for biosimilar switching practices.
- CMS and private insurers favor biosimilar substitution; some states require prescribing of biosimilars if deemed equivalent.
- Patent disputes may delay or modify biosimilar market penetration.
Key Takeaways
- The infliximab market experienced significant shifts after patent expirations in 2018-2019.
- Biosimilars now comprise a substantial market share, exerting downward pressure on prices.
- The average price for infliximab vials is expected to decline from approximately $2,000 in 2023 to below $1,800 by 2028.
- Market growth hinges on biosimilar adoption rates, regulatory policies, and indication expansions.
- Overall revenues for the originator drug are likely to decline due to increased competition, despite steady or growing volume.
FAQs
Q1: How will biosimilar entry affect Remicade’s market share?
A: Biosimilars are expected to capture 60% of the U.S. infliximab market by 2028, reducing Remicade’s share correspondingly.
Q2: Are there upcoming patent litigations that could influence prices?
A: Yes, patent disputes continue in the U.S. and Europe, potentially delaying biosimilar market expansion or leading to patent settlements affecting pricing.
Q3: What is the outlook for infliximab pricing outside the U.S.?
A: Price reductions are generally more gradual in Europe due to different reimbursement systems but follow similar downward trends driven by biosimilar competition.
Q4: Could new indications for infliximab change pricing dynamics?
A: Yes, approval of additional indications can increase demand and potentially stabilize prices, but biosimilar competition remains a key factor.
Q5: Will price erosion impact the profitability of remicade manufacturers?
A: Significant price competition and biosimilar adoption will likely compress margins, pressuring profitability unless offset by volume growth or new indications.
References
- IQVIA Medical Data, 2022.
- Wolfe Research, 2022.
- Scrip Intelligence, 2022.
- FDA Drug Approvals and Biosimilar Guidance, 2021.
- CMS Biosimilar Policy Updates, 2022.
